How is anesthesia reversal

Advanced Search. Sign In. Skip Nav Destination Article Navigation. Close mobile search navigation Article navigation. Volume , Issue 4. Previous Article Next Article. Competing Interests. Research Support. Article Navigation. Editorial Views October Murphy, M.

Address correspondence to Dr. Murphy: dgmurphy2 yahoo. This Site. Google Scholar. Aaron F. Kopman, M. Author and Article Information. Corresponding article on page Accepted for publication April 26, Anesthesiology October , Vol.

Connected Content. Get Permissions. View large Download slide. Search ADS. Residual curarisation: A comparative study of atracurium and pancuronium. Postoperative neuromuscular blockade: A comparison between atracurium, vecuronium, and pancuronium. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia.

A study of the deaths associated with anesthesia and surgery: Based on a study of , anesthesias in ten institutions , inclusive. Admissions to the intensive care unit after complications of anaesthetic techniques over 10 years. The first 5 years. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: Prospective propensity score matched cohort study. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications.

Browse By. How to reverse general anesthesia. Neuroscientists find that Ritalin could help bring surgical patients out of surgery much more quickly, with less grogginess. Publication Date :. Caption :. Credits :.

Brown and colleagues at MGH are studying the effects of stimulants that could be used to bring patients out of general anesthesia much faster.

One potential candidate is Ritalin, the drug commonly used to treat attention deficit hyperactivity disorder ADHD. In a study published online Sept.

Volume Article Contents Abstract. Conventional reversal of neuromuscular block. Anticholinesterase side-effects. Postoperative residual paralysis. Newer reversal agents. Human studies. Reversal of neuromuscular block. Srivastava , A. E-mail: alok. Oxford Academic. Cite Cite A. Select Format Select format. Abstract The use of anticholinesterases to reverse residual neuromuscular block is efficacious only if recovery is already established.

Table 1 Factors contributing to postoperative residual paralysis. Open in new tab. Open in new tab Download slide. Table 2 Q-Tc interval prolongation after sugammadex 4. Moxifloxacin mg. Largest time-matched mean Q-Tc interval difference to placebo ms 1.

Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Google Scholar Crossref. Search ADS. Inability to reverse pancuronium blockade in a patient with renal failure and hepatic disease. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. A study of anticholinesterase and anticurare effects of some cholinesterase inhibitors. Residual neuromuscular block is a risk factor for postoperative pulmonary complications.

A prospective, randomized, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Postoperative neuromuscular blockade: a comparison between atracurium, vecuronium, and pancuronium. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children.

Google Scholar PubMed. Dose responses for neostigmine and edrophonium as antagonists of mivacurium in adults and children. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Sugammadex 2. Chemical chelation as a novel method of NMB reversal: discovery of Org Neuromuscular block induced by rocuronium and reversed by the encapsulating agent Org can be re-established using the non-steroidal neuromuscular blockers succinylcholine and cis-atracurium.

Respiratory mechanics in anaesthetized patients after neostigmine-atropine. A comparison between patients with and without chronic obstructive pulmonary disease. Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation.

Postoperative residual curarization with cisatracurium and rocuronium infusions. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers.

Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. The action of certain esters and ethers of choline and their relation to muscarine. Reversal of rocuronium-induced 1. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys.

Time course of action of sugammadex Org on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.

Reversal of pancuronium induced block by selective relaxant binding agent sugammadex. Susceptibility to upper airway obstruction during partial neuromuscular block. Pharmacokinetics, pharmacodynamics and dose—response relationships of pancuronium in control and elderly subjects.

Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex.

Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org Reduced hypoxic chemosensitivity in partially paralyzed man. A new property of muscle relaxants? Effect of vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers.

Recovery from neuromuscular blockade: residual curarization following atracurium or vecuronium by bolus dosing or infusions. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. First human exposure of Org , a novel agent to reverse the action of rocuronium bromide.

The antagonism of curare: the cardiac effects of atropine and neostigmine. A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block.

Oxyaniliniums as acetylcholinesterase inhibitors for the reversal of neuromuscular block. Pattern of change of bronchomotor tone following reversal of neuromuscular blockade. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. Org reverses rocuronium-induced neuromuscular blockade in the cat without important haemodynamic effects.

Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. The doughnut and the hole: a new pharmacological concept for anaesthetists. Metabolism and excretion of 3-hydroxyphenyltrimethylammonium and neostigmine. Use of neostigmine in the antagonism of residual neuromuscular blockade produced by vecuronium.

Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery. Optimum time for neostigmine reversal of atracurium-induced neuromuscular blockade. Time to peak effect of neostigmine at antagonism of atracurium-, or vecuronium-induced neuromuscular block. Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function.

Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory?

Reversal of profound rocuronium NMB with sugammadex is faster than recovery from succinylcholine. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. Org causes selective reversal of neuromuscular block induced by steroidal NMBs in anaesthetized guinea pigs. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients.

Residual neuromuscular blockade after cardiac surgery: pancuronium vs rocuronium. Comparative times to peak effect and duration of action of neostigmine and pyridostigmine. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy.

Novel piperidinium and pyridinium agents as water-soluble acetylcholinesterase inhibitors for the reversal of neuromuscular blockade. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in paediatric and adult patients.

Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Effects of neostigmine and glycopyrrolate on pulmonary resistance in spinal cord injury.

Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly patients. Anticholinesterase drugs stimulate phosphatidylinositol response in rat tracheal slices. Heart block and prolonged Q-Tc interval following muscle relaxant reversal: a case report. Org sugammadex , a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block.

Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients.

Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis: a systematic review. Neuromuscular blockade induced by steroidal NMBs can be rapidly reversed by Org in anaesthetized monkey.

Effects of isoflurane and sevoflurane on the magnitude and time course of neuromuscular block produced by vecuronium, pancuronium and atracurium.

Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Update for nurse anesthetists. Part 3. Cyclodextrin introduction to anesthesia practice: form, function, and application. Discovery, development, and clinical applications of sugammadex sodium, a selective relaxant binding agent. Clearance of neostigmine from circulation during the antagonism of neuromuscular block.

Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.